Literature DB >> 9751705

Characterization of covalent adriamycin-DNA adducts.

S M Zeman1, D R Phillips, D M Crothers.   

Abstract

Adriamycin is a popular antineoplastic agent whose ability to form covalent adducts with DNA has been correlated to cellular apoptosis (programmed cell death) in tumor models. We have isolated and purified this adduct formed under oxido-reductive (Fenton) conditions in Tris buffer. We show by homo- and heteronuclear NMR spectroscopy that the covalent Adriamycin-DNA adduct is structurally equivalent to that resulting from direct reaction with formaldehyde. Covalent linkage of the drug to one of the DNA strands confers remarkable stability to the duplex, indicated by a 162-fold reduction in the rate of strand displacement compared with the complex with noncovalently bound drug. Glyceraldehyde also engenders covalent Adriamycin-DNA complexes, providing a possible relevant biological context for in vivo adduct formation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751705      PMCID: PMC21680          DOI: 10.1073/pnas.95.20.11561

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  16 in total

1.  Induction of stable transcriptional blockage sites by adriamycin: GpC specificity of apparent adriamycin-DNA adducts and dependence on iron(III) ions.

Authors:  C Cullinane; D R Phillips
Journal:  Biochemistry       Date:  1990-06-12       Impact factor: 3.162

2.  Production of formaldehyde and DNA-adriamycin or DNA-daunomycin adducts, initiated through redox chemistry of dithiothreitol/iron, xanthine oxidase/NADH/iron, or glutathione/iron.

Authors:  D J Taatjes; G Gaudiano; T H Koch
Journal:  Chem Res Toxicol       Date:  1997-09       Impact factor: 3.739

3.  Formaldehyde cross-links daunorubicin and DNA efficiently: HPLC and X-ray diffraction studies.

Authors:  A H Wang; Y G Gao; Y C Liaw; Y K Li
Journal:  Biochemistry       Date:  1991-04-23       Impact factor: 3.162

4.  Simultaneous incorporations of two anticancer drugs into DNA. The structures of formaldehyde-cross-linked adducts of daunorubicin-d(CG(araC)GCG) and doxorubicin-d(CA(araC)GTG) complexes at high resolution.

Authors:  H Zhang; Y G Gao; G A van der Marel; J H van Boom; A H Wang
Journal:  J Biol Chem       Date:  1993-05-15       Impact factor: 5.157

5.  Enzymatic activation and binding of adriamycin to nuclear DNA.

Authors:  B K Sinha; M A Trush; K A Kennedy; E G Mimnaugh
Journal:  Cancer Res       Date:  1984-07       Impact factor: 12.701

6.  Does adriamycin induce interstrand cross-links in DNA?

Authors:  C Cullinane; A van Rosmalen; D R Phillips
Journal:  Biochemistry       Date:  1994-04-19       Impact factor: 3.162

7.  Reappraisal of the association between adriamycin and iron.

Authors:  D Gelvan; A Samuni
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

8.  Interactions of hydroxyl radicals with tris (hydroxymethyl) aminomethane and Good's buffers containing hydroxymethyl or hydroxyethyl residues produce formaldehyde.

Authors:  H Shiraishi; M Kataoka; Y Morita; J Umemoto
Journal:  Free Radic Res Commun       Date:  1993

Review 9.  The anthracyclines: will we ever find a better doxorubicin?

Authors:  R B Weiss
Journal:  Semin Oncol       Date:  1992-12       Impact factor: 4.929

10.  DNA sequence-specific adducts of adriamycin and mitomycin C.

Authors:  D R Phillips; R J White; C Cullinane
Journal:  FEBS Lett       Date:  1989-03-27       Impact factor: 4.124

View more
  28 in total

Review 1.  DNA repair and personalized breast cancer therapy.

Authors:  Shu-Xia Li; Ashley Sjolund; Lyndsay Harris; Joann B Sweasy
Journal:  Environ Mol Mutagen       Date:  2010 Oct-Dec       Impact factor: 3.216

2.  Formaldehyde activation of mitoxantrone yields CpG and CpA specific DNA adducts.

Authors:  B S Parker; S M Cutts; C Cullinane; D R Phillips
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

3.  Interstrand cross-linking by adriamycin in nuclear and mitochondrial DNA of MCF-7 cells.

Authors:  C Cullinane; S M Cutts; C Panousis; D R Phillips
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

4.  Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index.

Authors:  Changhan Lee; Fernando M Safdie; Lizzia Raffaghello; Min Wei; Federica Madia; Edoardo Parrella; David Hwang; Pinchas Cohen; Giovanna Bianchi; Valter D Longo
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

5.  Pathway Engineering of Anthracyclines: Blazing Trails in Natural Product Glycodiversification.

Authors:  Katelyn V Brown; Benjamin Nji Wandi; Mikko Metsä-Ketelä; S Eric Nybo
Journal:  J Org Chem       Date:  2020-09-22       Impact factor: 4.354

6.  Anti-cancer effect of HIV-1 viral protein R on doxorubicin resistant neuroblastoma.

Authors:  Richard Y Zhao; Dong Liang; Ge Li; Christopher W Larrimore; Bernard L Mirkin
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

7.  Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.

Authors:  Rachael E Hawtin; David E Stockett; Jo Ann W Byl; Robert S McDowell; Tan Nguyen; Michelle R Arkin; Andrew Conroy; Wenjin Yang; Neil Osheroff; Judith A Fox
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

8.  Targeted sialic acid-doxorubicin prodrugs for intracellular delivery and cancer treatment.

Authors:  Sreeja Jayant; Jayant J Khandare; Yang Wang; Ajay P Singh; Nicholi Vorsa; Tamara Minko
Journal:  Pharm Res       Date:  2007-08-01       Impact factor: 4.200

9.  Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.

Authors:  Brian T Kalet; Meagan B McBryde; Joaquin M Espinosa; Tad H Koch
Journal:  J Med Chem       Date:  2007-08-16       Impact factor: 7.446

10.  A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues.

Authors:  Andrew T Lucas; Sara K O'Neal; Charlene M Santos; Taylor F White; William C Zamboni
Journal:  J Pharm Biomed Anal       Date:  2015-11-28       Impact factor: 3.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.